1. Role: Associate Dean. Scope: College. Description: Lead research enterprise of the College of Pharmacy. Represent the College at the HSC level. Mentor researchers. Date: 2020.
Vibhudutta Awasthi, Ph.D.
Professor and Associate Dean for Research
Pharmaceutical Sciences
Phone (405) 271-6593 x47331
Fax (405) -271-7505
Office CPB 309
Summary
My research interests are in the development of radiopharmaceuticals, small animal imaging and use of radiological imaging techniques to answer physiological questions. My current research focuses on the development of liposome encapsulated hemoglobin as an artificial oxygen carrier and he is studying cerebral oxygen metabolism using positron emission tomography. I am a board certified nuclear pharmacist with expertise in areas related to drug delivery, formulation development, nuclear pharmacy and small animal nuclear imaging.
Publications & Presentations
- 31. Rao G, Nkepang G, Yari H, Xu J, Houson H, Teng C, Awasthi V. Ubiquitin Receptor RPN13 Mediates the Inhibitory Interaction of Diphenyldihaloketones CLEFMA and EF24 with the 26S Proteasome. Frontiers in Chemistry . 2018; 6 : 392
32. Rao G, Houson H, Nkepang G, Yari H, Teng C, Awasthi V. Induction of Gut Proteasome Activity in Hemorrhagic Shock and its Recovery by Treatment with Diphenyldihaloketones CLEFMA and EF24. Am J Physiol Gastrointest Liver Physiol . 2018; 315 : G318-G327
33. Houson H, Nkepang G, Hedrick A, Awasthi V. Imaging of isoproterenol-induced myocardial injury with F-18-labeled fluoroglucaric acid in a rat model. Nucl Med Biol. 2018; 59 : 9-15
34. Awwad H O, Durand C D, Gonzalez L P, Tompkins P, Zhang Y, Lerner M R, Brackett D J, Sherry D M, Awasthi V, Standifer K. Post-blast treatment with Nociceptin/Orphanin FQ peptide (NOP) receptor antagonist reduces brain injury-induced hypoxia and signaling proteins in vestibulomotor-related brain regions. Behavioural brain research. 2018
35. Raghuvanshi D, Nkepang G, Hussain A, Yari H, Awasthi V. Stability studies on an anti-cancer drug 4-(3,5-bis(2-chlorobenzylidene)-4-oxo-piperidine-1-yl)-4-oxo-2-butenoic acid (CLEFMA) using a stability-indicating HPLC method. J Pharm Anal. 2017; 7 : 1-9
Grants
- 6. Pharmacotherapy of Traumatic Brain Injury Accompanied by Hemorrhagic Shock. NIH. Start Date: 2017. End Date: 2022.
7. Development of Bioactive Peptides for the Inhibition of Neuroinflammation and Neurotoxicity Induced by Amyloid-beta. Non-federal. Start Date: 2020. End Date: 2021.
8. Immunokinetics of superhydrophilic polymer-modified liposome encapsulated hemoglobin. Non-federal. Start Date: 2017. End Date: 2020.
9. PET Imaging Agent For Myocardial Infarction. NIH. Start Date: 2019. End Date: 2019.
10. Development of Tumor Proliferation PET Tracer FLT using a Low Cost Single Dose Automatic Production and Quality Control Biomarker Generator System. NIH. Start Date: 2016. End Date: 2017.
Awards and Honors
- 1. USPTO. Patent application issued. Date: 2015.
2. Journal of Pharmaceutical Sciences. Article selected as a featured research paper. Date: 2015.
3. Robert Glenn Rapp Foundation. Presidential Professor . Date: 2013.
4. Sandra K and David L Gilliland Chair in Nuclear Pharmacy . Date: 2012.
Education
- 1. Degree: Ph D. Sanjay Gandhi Postgraduate Institute of Medical Sciences . Date: 1994.
2. Degree: M. Pharm.. Dr. Hari Singh Gour Vishwavidyalaya, Sagar (Formerly, University of Sagar). Date: 1990.
3. Degree: B. Pharm. Dr. Hari Singh Gour Vishwavidyalaya, Sagar (Formerly, University of Sagar). Date: 1988.
Administrative Assignments
2. Role: Director. Scope: University. Description: Direction and conduct of nuclear imaging services for biomedical investigators; Production of PET radiotracers for preclinical imaging and preparation for regulatory compliance for clinical applications; Consultations with researchers about imaging and tracer applications. Date: 2007.
External Connections and Partnerships
no results